1. Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies
2. Ipilimumab in melanoma
3. (PBAC) A.P.B.A.C.Ipilimumab concentrate solution for I.V. infusion 50 mg in 10 mL 200 mg in 40 mL Yervoy® July 2011.2011; Available from:http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2011-07/pbac-psd-ipilimumab-july11
4. DicksonRB BagustA et al.Ipilimumab for previously treated unresectable malignant melanoma: a single technology appraisal.2011; Available from:https://www.nice.org.uk/guidance/ta268/documents/melanoma-stage-iii-or-iv-ipilimumab-evidence-review-group-report3
5. (PBAC) A.P.B.A.C.Ipilimumab concentrate solution for I. V infusion 50 mg in 10 mL 200 mg in 40 mL Yervoy® ‐ November 2012.2012; Available from:http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-11/ipilimumab